Recent developments highlight Immuron's product launches, sales growth, and clinical progress, reflecting ongoing business momentum and strategic execution.

• Immuron launched ProIBS® in the U.S. following its debut in Australia, expanding its digestive health product portfolio [N1].
• Fiscal year 2026 revenue rose 6%, with net loss narrowing and cash position improving, indicating operational progress [N2].
• The company marked its fourth consecutive quarter of sales growth in FY26, demonstrating consistent commercial traction [N3].
• Immuron reported continued sales growth in early 2026, supporting its market presence and product acceptance [N4].
• The company announced a rise in global revenue for Q1 2026, reflecting expanding geographic reach [N5].
• Record sales growth for Travelan® was reported in FY25, with sales reaching AUD 7.3 million, underscoring product demand [N6].
• Immuron provided strong sales projections and updates on clinical trials and product launches in mid-2025, indicating active pipeline management [N7].
• The launch of Calmino's ProIBS® in Australia and New Zealand for IBS-related symptoms treatment was announced in early 2025, broadening the product portfolio [N8].

Immuron's business model benefits from a proprietary platform technology with broad applicability in infectious diseases, supported by a growing commercial product portfolio including Travelan® and ProIBS®. The company has demonstrated consistent sales growth and is advancing clinical-stage drug candidates with potential to address significant unmet medical needs. Collaborations with the U.S. Department of Defense validate the platform's potential and provide funding support. Strong intellectual property protection and regulatory approvals in multiple markets underpin commercial opportunities. Recent launches and expanding geographic reach contribute to business momentum [S1][N1][N2][N3].

Risks include the clinical development uncertainties inherent in advancing drug candidates through regulatory approval processes. The P2TD clinical trial did not meet its primary endpoint for a twice-daily dosing regimen, requiring continuation with the established regimen, which may impact development timelines. Market acceptance and competitive pressures in the gastrointestinal health product space could affect sales growth. The company reported net losses and negative earnings per share in the latest fiscal year, indicating ongoing profitability challenges. Raw material price volatility, particularly for colostrum, may impact cost structures. Regulatory and reimbursement environments in key markets also pose risks [S1][S2].

Immuron's moat is anchored in its proprietary technology platform that produces targeted polyclonal antibodies via a unique process of immunizing dairy cows and harvesting hyper-immune bovine colostrum. This platform enables development of orally delivered biologics with applications across multiple infectious diseases. The company's intellectual property strategy secures composition of matter patents and broader technology patents, providing protection against competitors. Collaborations with the U.S. Department of Defense and clinical trial data supporting efficacy further strengthen its competitive position. Additionally, regulatory approvals and listings in multiple countries for its commercial products create barriers to entry for new competitors [S1].

• Clinical Development Risk: Advancing drug candidates through clinical trials and regulatory approvals involves uncertainties, as demonstrated by the P2TD study not meeting its primary endpoint for a dosing regimen.
• Market and Competitive Risk: The gastrointestinal health product market is competitive, and market acceptance of new products like ProIBS® may vary, impacting sales growth.
• Financial Risk: The company reported net losses and negative EPS in the latest fiscal year, indicating challenges in achieving profitability.
• Raw Material Price Volatility: Colostrum prices are subject to fluctuations due to dairy market conditions, which may affect production costs.
• Regulatory and Reimbursement Risk: Changes in regulatory requirements or reimbursement policies in key markets could affect commercialization and revenue.